Why conduct clinical trials in Norway?

Inven2 is responsible for the contractual and financial aspects of clinical trials and industry cooperation. We want to do our part to get more industrial players to conduct their trials in Norway. We work closely with hospitals, companies, the ecosystem and the authorities to encourage this. In this article, you can read more about what makes Norway an attractive country in which to conduct trials.

Norway is an attractive country for the clinical development of both pharmaceuticals and medical equipment. One of the reasons for this is that the Norwegian authorities facilitate clinical trial and medical innovation and prioritises this area. In 2020, the Ministry of Health and Care Services will publish a dedicated action plan for clinical trials. One of Norway’s main advantages is that we have a public and well-structured health service that treats all kinds of patients. Health service staff have high levels of academic expertise and are generally highly qualified.

The trial environments involved in clinical research and development are of a high international standard, from the testing departments involved in early-phase trials to the units involved in later phases. Norway has also conducted internationally recognised research and trials in the fields of cancer, paediatrics, gastroenterology, cardiovascular diseases and radiology.

Read more about the relevant trial institutions here.

Oslo University Hospital was for instance the only hospital in Europe that qualified for participation in the testing of the world’s first approved gene and cell therapy on children and adults.

All inhabitants of Norway have a unique personal identification number, which makes it possible to follow them from cradle to grave, and to compile information about individuals from a range of registers and biobanks. Norwegians are also very open to participating in clinical trials, and they are easy to recruit. Very few leave the study once they have enrolled. The Norwegian population is generally homogeneous, stable and highly educated.

The quality of health data is high and Norwegian hospitals have sound and well-integrated research environments. Norway is also home to several biobanks and registers available for clinical and medical research. You can read more about them here at Biobank Norway’s website. Du kan lese mer om dem her på Biobank Norway sine nettsider.

There is significant potential in combining health data from registers and biobanks to design even better trials and identify the right patients to participate. INSPIRE is such an initiative within the cancer field, and Norwegian authorities are now working to develop a health analysis platform to make it quicker and easier to retrieve data. You can read more about how to get access to register data at helsedata.no Du kan lese mer om hvordan du får tilgang til registerdata på helsedata.no

The following is a list of testing environments